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Abstract 
The availability of new topical preparations for the treatment of left sided ulcerative colitis offers a 
therapy optimization for many patients. Rectal application of steroids and 5-aminosalicylic acid (5-
ASA) is associated with fewer side effects and has a higher therapeutic efficacy in mild to moderate-
active left-sided colitis as compared to a systemic therapy. It is recommended in international 
guidelines; however, especially with respect to topical therapy guidelines may not be followed 
regularly. We investigated the use of topical therapy in the Swiss National IBD cohort study (SIBDCS).  
Sixteen percent of patients of the SIBDCS suffered from proctitis, 21% had procto-sigmoiditis and 
41% had pancolitis. Topical therapy with 5-ASA or corticosteroids was given in only 23% of patients 
with proctitis, whereas a combined systemic and topical treatment was given in 11%. Systemic oral 
treatment with 5-ASA without topical treatment was given in 29%. A subgroup of 8% received 
immunomodulators or anti-TNF antibodies. Side effects of topical or systemic 5-ASA or budesonide 
treatment were less frequently reported as compared to other medications. Topical treatment was 
frequently stopped over the disease course and not used for maintenance of remission. The quality 
of life was the same in patients with limited disease compared to patients with pancolitis. 
Topical treatment in proctitis patients was underused in the SIBDCS and not applied according to 
current guideline recommendations. Since topical treatment is safe and effective its use should be 
encouraged   
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Introduction 
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Ulcerative colitis (UC) is a chronic relapsing inflammatory disorder of the colon and besides Crohn’s 
disease (CD) one of the two major forms of inflammatory bowel disease (IBD).  Its incidence in 
Europe is estimated to be around 5 to 25 new patients per 100.000 inhabitants per year. The etiology 
of UC remains unclear and subsequently medical therapies are not available that may completely 
cure the disease.  The clinical presentation of UC is characterized by abdominal pain, diarrhea with or 
without hematochezia and mucosal ulcerations. UC is limited to the mucosa of the large intestine. It 
always involves the rectum and shows variable extension to the left sided or entire colon. 70% of the 
UC patients in population based studies exhibit only a proctitis/procto-sigmoiditis or left sided colitis. 
Only 30% will have extended disease (Solberg et al. 2009a). This may be different in a cohort such as 
the SIBDCS which includes 2/3 hospital treated patients having more severe of extensive disease. 
In addition to the varying extend of the disease there is a wide variation in the severity of UC. 
Clinically mild disease is associated with less than four bowel movements per day, with or without 
bloody stools but without systemic manifestations. Blood tests in patients with mild disease are 
usually normal. Moderate disease has been defined as more than four bowel movements per day 
with minor systemic manifestations. Severe disease describes is attributed to patients with more 
than six  bowel movements a day, fecal blood loss and systemic signs of inflammation. Classifications 
for disease severity show minor differences, however, the criteria for the discrimination of mild, 
moderate and severe disease remain more or less the same. An increased risk for the development 
of  colorectal carcinoma (CRC) in UC patients with long lasting pancolitis has been described (Eaden 
2004). This CRC risk appears to be reduced by sufficient anti-inflammatory medical therapy and by 
the achievement of mucosal healing. Proctitis appears not to be associated with increased CRC risk. 
The basic treatment in mild to moderate UC is 5-aminosalicylic acid (5-ASA; mesalazine or 
mesalamine) irrespective of the disease localization. However, in patients with proctitis or left sided 
colitis topical application of 5-ASA as suppository, enema or foam preparation is more effective as 
compared to systemic treatment (Gionchetti, P., et al., Review article: treatment of mild to moderate 
ulcerative colitis and pouchitis. Aliment Pharmacol Ther, 2002. 16 Suppl 4: p. 13-9). Topically 
administrated steroids are superior to placebo in this situation, however, inferior if compared to 
topical 5-ASA (Marshall, J.K. and E.J. Irvine, Rectal corticosteroids versus alternative treatments in 
ulcerative colitis: a meta-analysis. Gut, 1997. 40(6): p. 775-81.;  Campieri, M., et al., Efficacy of 5-
aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sci, 1987. 
32(12 Suppl): p. 67S-70S). Therefore the treatment of choice in mild to moderate left-sided colitis is 
5-ASA foams or enemas (Marshall, J.K. and E.J. Irvine, Rectal aminosalicylate therapy for distal 
ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther, 1995. 9(3): p. 293-300.).  During acute 
flares of the disease enemas are frequently less well tolerated due to their volume of up to 100 ml 
(Campieri, M., et al., 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin 
Gastroenterol, 1988. 10(4): p. 406-9). As usually the rectum is affected by the most severe 
inflammation while containing the highest number of sensory nerves it is easily understandably by 
high volume enemas cause discomfort and urgency. Foam preparations are usually better tolerated 
and accepted by patients with acute flares of left sided colitis (Regueiro, M., et al., Medical 
management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic 
trials. Inflamm Bowel Dis, 2006. 12(10): p. 979-94.)  
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Compliance and patient acceptance is essential for the success of a rectal therapy (Katz S, 
Lichtenstein GR, Safdi MA. 5-ASA Dose-Response: Maximizing Efficacy and Adherence. Gastroenterol 
Hepatol (N Y). 2010;6(2 Suppl 3):1-16;       Prantera C, Rizzi M. 5-ASA in ulcerative colitis: improving 
treatment compliance. World J Gastroenterol. 2009;15:4353-5.     Kane SV, Brixner D, Rubin DT, 
Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care 
Pharm. 2008;14:s2-12;      Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in 
ulcerative colitis: effect on patient outcomes Drugs. 2008;68:1089-103.) In general patients well 
accept to perform topical therapy if explained properly  (Hawthorne AB, Rubin G, Ghosh S. Review 
article: medication non-adherence in ulcerative colitis--strategies to improve adherence with 
mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008;27:1157-66;     Kane SV. 
Systematic review: adherence issues in the treatment of ulcerative colitis.  Aliment Pharmacol Ther. 
2006;23:577-85.). It is not the case that a topical therapy per se is associated with lower adherence 
and compliance. Only in very severe disease application of topical therapy may cause pain and 
discomfort. Therefore, topical therapy may be paused during severe disease flares. 
As mentioned foam preparations are better tolerated as compared to enemas (Marshall JK, Thabane 
M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of 
remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115.;    James SL, Irving 
PM, Gearry RB, Gibson PR. Management of distal ulcerative colitis: frequently asked questions 
analysis. Intern Med J. 2008;38:114-9.     Cortot A, Maetz D, Degoutte E, Delette O, Meunier P, Tan G, 
Cazals JB, Dewit O, Hebuterne X, Beorchia S, Grunberg B, Leprince E, D'Haens G, Forestier S, Idier I, 
Lémann M.  Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative 
colitis. Am J Gastroenterol. 2008; 103:3106-14;   
Pokrotnieks J, Marlicz K, Paradowski L, Margus B, Zaborowski P, Greinwald R. Efficacy and tolerability 
of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, 
placebo-controlled study. Aliment Pharmacol Ther. 2000; 14:1191-8). 5-ASA foam preparations have 
a similar distribution pattern as compared to enemas (Campieri M, Corbelli C, Gionchetti P, Brignola 
C, Belluzzi A, Di Febo G, Zagni P, Brunetti G, Miglioli M, Barbara L.  Spread and distribution of 5-ASA 
colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci. 1992; 37:1890-7.). 5-ASA 
suppositories in a dosage of 1g/day are the preferred therapy of mild to moderate proctitis (Marshall 
JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for 
induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115.) A meta-
analysis of 11 studies showed a median remission rate of 67% for rectal 5-ASA (as compared with 7 
to 11% for placebo (Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a 
meta-analysis. Aliment Pharmacol Ther. 1995; 9: 293-300.). A study by Eliakim and co-workers with a 
low volume rectal 5-ASA foam preparation showed remission rates of 78% in patients with mainly 
proctitis (Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-Meir S, Lavy A, Mueller 
R, Greinwald R, Chermesh I, Gross V; International Salofalk Foam Study Group. Clinical trial: 
randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-
volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther. 2007 ; 26: 1237-
49.) 
Topical steroids should be used for patients that are intolerant to 5-ASA. However, an additive 
therapy of topical 5-ASA and steroid may also be beneficial (Mulder CJ, Fockens P, Meijer JW, van der 
Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 
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g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J 
Gastroenterol Hepatol. 1996;8:549-53.). 
In moderate active distal colitis topical 5-ASA therapy in combination with oral 5-ASA therapy has 
proven to be highly effective (88% response after 6 weeks) (Safdi M, DeMicco M, Sninsky C, Banks P, 
Wruble L, Deren J, Koval G, Nichols T, Targan S, Fleishman C, Wiita B. A double-blind comparison of 
oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. 
Am J Gastroenterol. 1997; 92: 1867-71.) A meta-analysis of 33 studies showed that topical 5-ASA is 
more effective as compared to topical conventional steroids or budesonide (Marshall JK, Thabane M, 
Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission 
in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115.;          Marshall JK, Irvine EJ. 
Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997; 
40: 775-81.         Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal 
ulcerative colitis. Am J Gastroenterol. 2000;95: 1628-36.) 
Remission also can be maintained by topical treatment of at least two years duration Katz S, 
Lichtenstein GR, Safdi MA. 5-ASA Dose-Response: Maximizing Efficacy and Adherence. Gastroenterol 
Hepatol (N Y). 2010;6(2 Suppl 3):1-16;       Prantera C, Rizzi M. 5-ASA in ulcerative colitis: improving 
treatment compliance. World J Gastroenterol. 2009;15:4353-5.     Kane SV, Brixner D, Rubin DT, 
Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care 
Pharm. 2008;14:s2-12;     Rogler G. Medical management of ulcerative colitis. Dig Dis. 2009;27:542-9.  
Travis SP, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, Colombel JF, D'Haens G, 
Ghosh S, Marteau P, Kruis W, Mortensen NJ, Penninckx F, Gassull M; for the European Crohn's and 
Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative 
colitis: Current management. Crohns Colitis. 2008;2:24-62.). For maintenance 3 g of 5-ASA total per 
week are recommended. 
A topical therapy in distal UC has several advantages. The majority of patients has a distal disease 
type ( Rogler G. Medical management of ulcerative colitis. Dig Dis. 2009;27:542-9.    Lakatos PL, 
Lakatos L. Ulcerative proctitis: a review of pharmacotherapy and management. Expert Opin 
Pharmacother. 2008;9:741-9). Thus a topical therapy should be applied in the majority of patients 
with UC as the success rate is higher as compared to oral therapy and side effects are fewer. 
However, ther are reports of an underuse of topical therapies despite guideline recommendations 
(Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA. Are patients with inflammatory 
bowel disease receiving optimal care? Am J Gastroenterol. 2005;100:1357-61.) 
The aim of this study was to investigate the use of topical and systemic therapies in patients with 
ulcerative colitis of the Swiss IBD cohort study 
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Methods 
Data of the Swiss National Cohort study were used to perform this study. The cohort is described 
elsewhere (Valery you may know the best reference). The aim of the study was the characterization 
of the use of topical versus oral therapies in UC patients within the Swiss IBD cohort. We performed a 
cross-sectional (transversal) analysis of data of the Swiss IBD cohort. Furthermore a longitudinal data 
analysis was done in a subgroup of patients where the data is available.  
Treatments of interest were classified as follows: systemic (Oral 5-ASA, budesonide), topical (topical 
5-ASA, topical Steroids), combination of both systemic and topical, immunomodulators 
(Azathioprine, 6-Mercaptopurine, Methotrexate), anti-TNF alpha antibodies (Infliximab, Adalimumab, 
Certolizumab-pegol), other therapies (e.g. antiobiotics, steroids), and no therapy at all.  
Self-completed SF36 quality of life questionnaires were used to assess life conditions of patients at 
the different stages of follow-up. 
 
Statistics 
We used chi-squared test to estimate differences between independent groups for categorical 
variables, and Kruskall-Wallis one way analysis of variance to compare medians of continuous 
variables among independent groups. A level of 5% was considered to be statistically significant. 
 
Results 
General description of the study population 
Among 1961 patients with IBD enrolled in the Swiss IBD Cohort between 2006 and 2011, 800 (40.8%) 
were originally diagnosed with UC. During follow-up, 10 patients experienced a change of diagnosis, 
either to CD or to indeterminate colitis. Therefore, a total of 790 patients were included in this study. 
538 of those patients (68.1%) completed a 1st-year follow-up, 381 (48.2%) completed a 2nd-year 
follow-up, and 263 (33.3%) completed a 3rd-year follow-up.  
The baseline clinical characteristics of the study population are presented in Table 1. Little more than 
the half were males (N=429), with mean age of 44.3 years (SD 14.5, range 16 to 85), and a mean 
disease duration of almost 11 years (SD 8.7, range 0 to 49). 
Males more often had an extensive colitis (44.3% vs 36%) and women a proctosigmoiditis or proctitis. 
(23.3% vs 18.0%, respectively 18.8% vs 14.2%, p=0.025). 
Among the 526 patients that were followed for at least one year and for which disease location was 
documented, 74 (14.1%) experienced a regression of the disease extension, 40 (7.6%) an expansion 
of the disease extension. 
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Medication 
We analyzed the use of medication for all 773 patients with known disease location according to the 
subgroups of patients with different intestinal involvement. Topical treatment was mainly used in 
patients with proctitis and proctosigmoiditis. Twenty-nine percent of the patients were exclusively 
orally treated with 5-ASA, whereas topical therapy was given in 25.6% of patients with proctitis. A 
fraction of patients  (13%) received oral and topical treatment simultaneously.  A total of 50.5% of 
proctitis patients were treated exclusively with oral or iv medication. The use of systemic drugs was 
less frequent for proctitis (29.5%) than for the other disease locations (p=0.009). (Table I)  
In patients with proctosigmoiditis a total 80% of patients were treated systemically. Proportion of 
topical drug use decreased with respect to disease extension from 24% for proctosigmoiditis to 
13.1% for pancolitis  (p=0.001) (Figure 1). 
Interestingly the use of immunomodulators differed significantly between the groups. They were 
most frequently used in patients with left sided colitis, followed by patients with a pancolitis 
(p=0.001). However, 4.7% of patients with proctitis and 12.4% of patients with proctosigmoiditis 
were treated with immunomodulators (Table I). 
The use of anti TNF antibodies varied between the groups. Six percent of patients with pancolitis and 
left-sided colitis were treated with this medication compared to 3.1 percent of patient with proctitis 
but the difference between all groups was not found to be statistically significant (p=0.464)(Table I).  
More than one third of all patients with ulcerative colitis (38.9%, N=301) were treated with systemic 
5-ASA without topical treatment, whereas only 9.6% (N=74) were exclusively treated with topical 
drugs, and 1 out of 10 (N=86) were treated with a combination of systemic and topical medication. 
Topical steroids or budesonide were relatively infrequently used in the Swiss IBD cohort, whereas the 
mainstay of topical therapy consisted of topical 5-ASA formulations. 
 
Side effects of medical treatment 
Treatment with 5-ASA and budesonide (orally or topically) was significantly less frequently associated 
with side effects compared to immunomodulator or anti-TNF-alpha antibody treatment (p<0.001) . 
Oral 5-ASA was the most common therapy (336/790, 42.5%), and patients experienced side effects in 
13.1% of the cases. Most common side effects of oral 5-ASA treatment were asthma, skin rash, 
interstitial nephritis, diarrhea and pancreatitis.  Topical 5-ASA or topical steroids were given in a total 
334 cases (42.3%), while 65 patients (8.2%) were treated by both. Most common side effects of 
topical 5-ASA treatment were painful application of treatment, diarrhea due to intolernance, and 
skin rash.  Side effects occurred in 25 cases out of 334 (7.5%) patients treated with topical therapies. 
Immunomodulators were given in 239 out of 790 cases (30.3%), leading to 116 occurrences of side 
effects (48.5%). Side effects for anti-TNF alpha antibody treatment were described in 24% of the 
cases. 
Change of treatment 
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We were interested how long patients will remain on a topical treatment in contrast to a systemic 
treatment. For patients under a topical therapy, change of medication occurs more frequently than 
in those under a systemic therapy (up to more than 50% of the cases). Change is made generally 
either to a fully systemic treatment (19 cases out of 58, 32.7%), or either to an additional systemic 
drug (13 out of 58, 22.4%). For patients under a systemic-topical combined treatment, change of 
drug is mainly an interruption of the topical treatment (42 cases out of 69, 60.9%). For patients under 
systemic drugs only, at least 70% do not have to change their therapy at any stage of the follow-up. 
When they have to, in more than 30% of the cases an additional topical drug is given (36 cases out of 
118 over all period), while only 14% change to a fully topical treatment (16 out of 118)(Table 4). 
 
Quality of life 
We were interested whether the quality of life was different in patients with limited disease in 
contrast to patients with pancolitis. The physical and mental components were measured by the SF 
36 questionnaire. Patients with limited disease had similar scores compared to patients with 
pancolitis. Mental score seemed to be lower in proctosigmoiditis patients than in others, at follow-up 
2 (p=0.036)(Table 5). 
 
Discussion 
In this study we investigated the use of rectal therapies with 5-ASA and steroids in the Swiss national 
IBD cohort. Topical treatment was most frequently used in patients with proctitis. The proportion of 
topical drug use decreased significantly with respect to an increase of intestinal involvement. The 
data of the Swiss national cohort study show that 57% of the patients had a colitis limited to the 
rectum or to the left colon. Our study revealed that oral 5-ASA was more frequently given in patients 
with proctitis than rectal formulations. Several studies showed the efficacy of rectal treatment with 
suppositories at a dosage of 1 g /day(James SL, Marshall JK, Casellas F, D'Arienzo A). Rectal foams can 
be alternatively used. Rectal 5-ASA applications achieve remission rates in the literature around 67% 
(Marshall JK). In another study 78% of patients came into remission using a 5-ASA foam (Eliakim R). 
Topical steroids should be used in patients intolerant or refractory to 5-ASA products. They can be 
added to a 5-ASA treatment (Mulder CJ).  
In patients with proctosigmoiditis 5-ASA therapy has also been shown to be effective at a dosage of 2 
g/d (Safdi M). Interestingly it was demonstrated that the combination of rectal and oral 5-ASA 
increased the efficiency of treatment (Safdi M).  After a treatment period of 6 weeks with 2.4 g of 
oral 5-ASA 33% had no fecal blood whereas 54% of rectally treated patients and 88% of patients 
treated with an oral rectal combination treatment did respond to the therapy.   
It is unclear why the frequency of rectal therapy is relatively low in Switzerland. The data in the 
literature clearly show a superiority of rectal treatment compared to oral treatment in patients with 
proctitis and proctosigmoiditis. We assume that most Swiss gastroenterologists know of these 
details, therefore other factors seem to influence the treatment decisions. In the follow up studies in 
this paper we realized that topical treatment was frequently stopped and not used as a maintenance 
treatment. We speculate that patients prefer to take capsules instead of suppositories, enemas or 
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rectal foams. To overcome this fact, better information and teaching of our patients may be helpful. 
Even in the maintenance of remission rectal 5-ASA formulations are helpful in patients with proctitis 
or proctosigmoiditis. The patients should be encouraged to maintain the treatment with a minimal 
weekly dose of 3g of 5-ASA (D'Albasio G, Piodi LP).  3-64-74-76-98-118-113-6 
In our study rectal 5-ASA products were significantly more frequently given than steroids. In one 
study the efficacy of budesonide versus mesalazine enemas has been compared in patients with left-
sided ulcerative colitis. Clinical remission at week 4 was achieved in 63.5% of budesonide and 77.2% 
of mesalazine treated patients (p<0.05) (Hartmann). Furthermore, a meta-analysis showed a higher 
efficiency of rectal 5-ASA treatments compared to topical steroids (Marshall JK, Marshall JK, Marshall 
JK). However, the combination of rectal steroids and 5-ASAs seems to be beneficial (Mulder CJ). 
In our cohort only a minority of patients with pancolitis received rectal therapy. Since urgency and 
high stool frequency are related to a rectal involvement a proportion of these patients may profit of 
an additional rectal therapy. A study proofed the efficacy of rectal therapy in patients with mild to 
moderate pancolitis in the combination with oral 5-ASA (Marteau P). 
No difference of quality of life was found in patients regarding to their intestinal involvement. This 
indicates that patients with only limited disease may suffer as much as patients with pancolitis. 
Therefore, patients with only a limited intestinal involvement will possibly profit of an optimization of 
their treatment regarding their quality of life. 
Rectal treatment, however, has its limitations. A subgroup of patients is unable to retain the enema. 
Therefore, rectal foams have been developed. The comparison between mesalamine foams versus 
mesalamine liquid enema in patients with active left-sided ulcerative colitis showed a not significant 
lower remission rate induced by the foam formulations. (Cortot). Despite of the fact that topical 
treatment may be more efficient than oral treatment a subgroup of patients does not feel 
comfortable to do the therapy on a daily basis. Therefore, there have been attempts for other galenic 
formulations to avoid the rectal administration. A new budesonide MMX extended-release tablet has 
been investigated in a trial that showed that 47% of patients reached a CAI reduction by 50% in 
contrast to placebo (33%). (D’haens).  
In this study, the frequency of side effects in patients treated with topically or orally given 5-ASA 
products was low compared to those treated with immunomodulators or anti-TNF-antibodies. This is 
in accordance to other papers (Ford). 
Due to the fact that university hospitals included the majority of the patients in this cohort, there 
may be a bias leading to an elevated frequency of pancolitis patients (40.5%).  In another cohort only 
22% of patients with ulcerative colitis suffered from pancolitis (Lakatos). Furthermore, the disease 
activity of our patients might be higher than in a population based cohort.  
In summary, there are several advantages of rectal treatment with 5-ASA or topical steroids in 
patients with ulcerative colitis. This includes a high therapeutic efficacy and low side effects. Due to 
these advantages physicians should encourage their patients to use rectal therapies. With the 
increasing number of rectal formulations on the market (suppositories, enema, low volume foam) 
most patients with ulcerative colitis will find an agreeable product. 
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 Total, N (%) 
Patients  
  Males 429 (54.3) 
Age, y  
  Mean (SD, range) 44.3 (14.5, 16-85) 
Age at 1st symptoms, y  
  Mean (SD, range) 32.1 (13.1, 3-78) 
Disease duration, y  
  Mean (SD, range) 10.8 (8.7, 0-49) 
Current disease location  
  Pancolitis 320 (40.5) 
  Left Sided Colitis 163 (20.6) 
  Proctosigmoiditis 161 (20.4) 
  Proctitis 129 (16.3) 
  Unknown or unclear 17 (2.2) 
Table 1: Baseline characteristics of study population. 
 
 
 
Figure 1: Medication according to disease location. 
 
 
 
 11 
 Proctitis 
N (%) 
Proctosigmoiditis 
N (%) 
Left-sided colitis 
N (%) 
Pancolitis 
N (%) 
total 
N (%) 
Location, N(%) 129(16.7) 161(20.8) 163(21.1) 320(41.4) 773 
Systemic      
  Oral 5-ASA 37(28.7) 64(39.7) 57(35.0) 127(39.7) 285(36.9) 
  Budesonide 0(0.0) 2(1.2) 1(0.6) 5(1.6) 8(1.0) 
  Oral 5-ASA, Budesonide 1(0.8) 3(1.9) 0(0.0) 3(0.9) 7(0.9) 
     Total systemic 38(29.5) 69(42.8) 58(35.6) 135(42.2) 301(38.9) 
Topical      
  Topical 5-ASA 30(23.3) 8(5.0) 7(4.3) 15(4.7) 60(7.8) 
  Topical Steroids 3(2.3) 3(1.9) 2(1.2) 3(0.9) 11(1.4) 
  Topical 5-ASA, Topical Steroids 0(0.0) 0(0.0) 2(1.2) 1(0.3) 3(0.4) 
     Total topical 33(25.6) 11(16.9) 11(6.7) 19(5.9) 74(9.6) 
Systemic and Topical      
  Oral 5-ASA, Topical 5-ASA 14(10.8) 23(14.3) 13(8.0) 18(5.6) 68(8.8) 
  Oral 5-ASA, Topical Steroids 2(1.6) 3(1.9) 4(2.5) 4(1.3) 13(1.7) 
  Oral 5-ASA, Topical 5-ASA, Budesonide 0(0.0) 1(0.6) 0(0.0) 0(0.0) 1(0.1) 
  Oral 5-ASA, Topical 5-ASA, Topical Steroids 1(0.8) 1(0.6) 1(0.6) 0(0.0) 3(0.4) 
  Oral 5-ASA, Budesonide, Topical Steroids 0(0.0) 0(0.0) 0(0.0) 1(0.3) 1(0.1) 
     Total systemic and topical 17(13.2) 28(17.4) 18(11.1) 23(7.2) 86(11.1) 
Immunomodulators 6(4.7) 20(12.4) 34(20.9) 45(14.0) 105(13.6) 
Anti-TNF alphas 4(3.1) 12(7.4) 10(6.1) 19(6.0) 45(5.8) 
Other therapy 17(13.2) 14(8.7) 14(8.6) 32(10.0) 77(9.9) 
No therapy 14(10.8) 7(4.4) 18(11.0) 47(14.7) 86(11.1) 
Table 2: Medication for all 773UC patients with known disease location. 
Table 2 shows medication for all 773 patients with known disease location. More than one third of the patients (38.9%, N=301) were treated with only 
systemic anti-inflammatory drugs or budesonide, 9.6% (N=74) were treated with topical drugs, and 1 out of 10 (N=86) were treated with a combination of 
systemic and topical medication. Immunomodulating drugs were used in 105 cases (13.6%), biological agents in 45 cases (5.8%). 
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Side effects 
 
 Past therapy % Side effect % 
Oral 5-ASA 336 42.5 44 13.1 
Budesonide 74 9.4 1 1.4 
Topical 5-ASA 250 31.6 18 7.2 
Topical Steroids 149 18.9 7 4.7 
Immunomodulators 239 30.3 116 48.5 
Anti-TNF alphas 96 12.2 23 24.0 
Table 3: Past therapies and side effects for stopped therapies 
Table 3 shows past treatment, used by UC patients, as well as reported side effects that led to 
therapy cessation. Oral 5-ASA was the most common past therapy (336/790, 42.5%), and patients 
experienced side effects in 13.1% of the cases. Topical 5-ASA or Topical Steroids were given in a total 
334 cases (42.3%), while 65 patients (8.2%) were treated by both. Combined side effects occurrence 
for topical therapy is 25 cases out of 334 (7.5%). Immunomodulator drugs were given in 239 out of 
790 cases (30.3%), leading to 116 occurences of side effects (48.5%). 
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Change of treatment 
 
From Enrollment to Follow-up 1: 
Enroll/FUp1 Systemic Topical Syst&Topic Immunomod Anti-TNF Other No therapy 
Systemic 142 
(71.0%) 
10 16 15 2 3 12 
Topical 10 25 
(46.3%) 
9 3 1 2 4 
Syst&Topic 28 4 25 
(37.9%) 
1 1 3 4 
From Follow-up 1 to Follow-up 2: 
FUp1/FUp2 Systemic Topical Syst&Topic Immunomod Anti-TNF Other No therapy 
Systemic 90  
(70.3%) 
4 12 9 5 3 5 
Topical 8 19 
(47.5%) 
3 2 2 5 1 
Syst&Topic 7 4 20  
(54.1%) 
2 1 3 0 
From Follow-up 2 to Follow-up 3: 
FUp2/FUp3 Systemic Topical Syst&Topic Immunomod Anti-TNF Other No therapy 
Systemic 57  
(72.2%) 
2 8 4 3 4 1 
Topical 1 11 
(57.9%) 
1 1 1 1 3 
Syst&Topic 7 2 8  
(42.1%) 
0 0 2 0 
Table 4: Change of medication between different stages of follow-up 
 
Table 4  shows the change of medication between different stages of follow-up. Overall number of 
patients is decreasing since not every patient has filled all yearly follow-ups. For patients under 
systemic drugs only, we observed a total of 118 treatment switches over the whole period, which 
means that at least 70% do not have to change their therapy at any stage of the follow-up. When 
they have to, in more than 30% of the cases an additional topical drug is given (36 cases out of 118 
over all period), while only 14% change to a fully topical treatment (16 out of 118). For patients 
under a topical therapy, change of medication occurs in 58 total cases over the whole period (more 
than 50% of the cases)., which is more often than the systemic drugs group. Change is made 
generally either to a fully systemic treatment (19 cases out of 58, 32.7%), or either to an additional 
systemic drug (13 out of 58, 22.4%). For patients under a systemic-topical combined treatment, 
change of drug is mainly an interruption of the topical treatment (42 cases out of 69 total switches 
were made towards a systemic drug only, which represents more than 60% of the cases).  
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Quality of life 
 
 Proctitis Proctosigmoiditis Left Sided colitis Pancolitis  
Enrollment      
  Physical 53.0 51.1 51.2 51.3 P=0.150 
  Mental 47.3 46.0 46.7 48.2 P=0.327 
Follow-up 1      
  Physical 55.2 52.9 50.2 52.8 P=0.057 
  Mental 48.9 48.7 48.6 51.2 P=0.825 
Follow-up 2      
  Physical 55.1 51.9 53.4 54.2 P=0.063 
  Mental 49.0 46.4 49.9 50.7 P=0.036 
Follow-up 3      
  Physical 54.7 51.5 51.6 56.0 P=0.125 
  Mental 51.2 48.4 50.6 50.7 P=0.808 
Table 5: Median of SF36 Physical and Mental component scores according to disease location for 
different times of follow-up. 
 
Table 5 summarizes the median of both Physical and Mental component scores of the SF36 
questionnaire at different times of follow-up and according to disease location. Mental score seems 
to be lower in proctosigmoiditis patients than in others, at follow-up 2 (p=0.036). No statistical 
difference was found, except for Mental score at follow-up 2. 
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